These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
232 related articles for article (PubMed ID: 38399271)
1. The Design, Synthesis and Mechanism of Action of Paxlovid, a Protease Inhibitor Drug Combination for the Treatment of COVID-19. Bege M; Borbás A Pharmaceutics; 2024 Feb; 16(2):. PubMed ID: 38399271 [TBL] [Abstract][Full Text] [Related]
2. Genetic Surveillance of SARS-CoV-2 M Lee JT; Yang Q; Gribenko A; Perrin BS; Zhu Y; Cardin R; Liberator PA; Anderson AS; Hao L mBio; 2022 Aug; 13(4):e0086922. PubMed ID: 35862764 [TBL] [Abstract][Full Text] [Related]
3. Paxlovid (Nirmatrelvir/Ritonavir): A new approach to Covid-19 therapy? Hashemian SMR; Sheida A; Taghizadieh M; Memar MY; Hamblin MR; Bannazadeh Baghi H; Sadri Nahand J; Asemi Z; Mirzaei H Biomed Pharmacother; 2023 Jun; 162():114367. PubMed ID: 37018987 [TBL] [Abstract][Full Text] [Related]
4. Disposition of Nirmatrelvir, an Orally Bioavailable Inhibitor of SARS-CoV-2 3C-Like Protease, across Animals and Humans. Eng H; Dantonio AL; Kadar EP; Obach RS; Di L; Lin J; Patel NC; Boras B; Walker GS; Novak JJ; Kimoto E; Singh RSP; Kalgutkar AS Drug Metab Dispos; 2022 May; 50(5):576-590. PubMed ID: 35153195 [TBL] [Abstract][Full Text] [Related]
5. Nirmatrelvir combined with ritonavir for preventing and treating COVID-19. Reis S; Metzendorf MI; Kuehn R; Popp M; Gagyor I; Kranke P; Meybohm P; Skoetz N; Weibel S Cochrane Database Syst Rev; 2022 Sep; 9(9):CD015395. PubMed ID: 36126225 [TBL] [Abstract][Full Text] [Related]
6. Paxlovid: Mechanism of Action, Synthesis, and Marzi M; Vakil MK; Bahmanyar M; Zarenezhad E Biomed Res Int; 2022; 2022():7341493. PubMed ID: 35845944 [TBL] [Abstract][Full Text] [Related]
7. Preclinical discovery and development of nirmatrelvir/ritonavir combinational therapy for the treatment of COVID-19 and the lessons learned from SARS-COV-2 variants. Pagliano P; Spera A; Sellitto C; Scarpati G; Folliero V; Piazza O; Franci G; Conti V; Ascione T Expert Opin Drug Discov; 2023; 18(12):1301-1311. PubMed ID: 37614103 [TBL] [Abstract][Full Text] [Related]
8. Optimizing the use of Paxlovid in clinical practice. McCarthy MW Drugs Today (Barc); 2022 Nov; 58(11):539-546. PubMed ID: 36422515 [TBL] [Abstract][Full Text] [Related]
9. Global prevalence of SARS-CoV-2 3CL protease mutations associated with nirmatrelvir or ensitrelvir resistance. Ip JD; Wing-Ho Chu A; Chan WM; Cheuk-Ying Leung R; Umer Abdullah SM; Sun Y; Kai-Wang To K EBioMedicine; 2023 May; 91():104559. PubMed ID: 37060743 [TBL] [Abstract][Full Text] [Related]
10. [Nirmatrelvir plus ritonavir (Paxlovid) a potent SARS-CoV-2 3CLpro protease inhibitor combination]. Reina J; Iglesias C Rev Esp Quimioter; 2022 Jun; 35(3):236-240. PubMed ID: 35183067 [TBL] [Abstract][Full Text] [Related]
11. The history, mechanism, and perspectives of nirmatrelvir (PF-07321332): an orally bioavailable main protease inhibitor used in combination with ritonavir to reduce COVID-19-related hospitalizations. Joyce RP; Hu VW; Wang J Med Chem Res; 2022; 31(10):1637-1646. PubMed ID: 36060104 [TBL] [Abstract][Full Text] [Related]
12. SARS-CoV-2 main protease inhibitors: What is moving in the field of peptides and peptidomimetics? Algar-Lizana S; Bonache MÁ; González-Muñiz R J Pept Sci; 2023 May; 29(5):e3467. PubMed ID: 36479966 [TBL] [Abstract][Full Text] [Related]
13. Oral Nirmatrelvir/Ritonavir Therapy for COVID-19: The Dawn in the Dark? Hung YP; Lee JC; Chiu CW; Lee CC; Tsai PJ; Hsu IL; Ko WC Antibiotics (Basel); 2022 Feb; 11(2):. PubMed ID: 35203821 [TBL] [Abstract][Full Text] [Related]
14. Paxlovid mouth likely is mediated by activation of the TAS2R1 bitter receptor by nirmatrelvir. Caronia L; Xi R; Margolskee RF; Jiang P Biochem Biophys Res Commun; 2023 Nov; 682():138-140. PubMed ID: 37806252 [TBL] [Abstract][Full Text] [Related]
15. The efficacy of Paxlovid against COVID-19 is the result of the tight molecular docking between M Dawood AA Adv Med Sci; 2023 Mar; 68(1):1-9. PubMed ID: 36368287 [TBL] [Abstract][Full Text] [Related]
16. Therapeutic Drug Monitoring and Dosage Adjustments of Immunosuppressive Drugs When Combined With Nirmatrelvir/Ritonavir in Patients With COVID-19. Lemaitre F; Budde K; Van Gelder T; Bergan S; Lawson R; Noceti O; Venkataramanan R; Elens L; Moes DJAR; Hesselink DA; Pawinski T; Johnson-Davis KL; De Winter BCM; Pattanaik S; Brunet M; Masuda S; Langman LJ Ther Drug Monit; 2023 Apr; 45(2):191-199. PubMed ID: 35944126 [TBL] [Abstract][Full Text] [Related]
17. A Comprehensive Review of the Clinical Pharmacokinetics, Pharmacodynamics, and Drug Interactions of Nirmatrelvir/Ritonavir. Gerhart J; Cox DS; Singh RSP; Chan PLS; Rao R; Allen R; Shi H; Masters JC; Damle B Clin Pharmacokinet; 2024 Jan; 63(1):27-42. PubMed ID: 38177893 [TBL] [Abstract][Full Text] [Related]
19. Interactions of the Anti-SARS-CoV-2 Agents Molnupiravir and Nirmatrelvir/Paxlovid with Human Drug Transporters. Bakos É; Temesszentandrási-Ambrus C; Özvegy-Laczka C; Gáborik Z; Sarkadi B; Telbisz Á Int J Mol Sci; 2023 Jul; 24(14):. PubMed ID: 37510996 [TBL] [Abstract][Full Text] [Related]
20. Advances and challenges in using nirmatrelvir and its derivatives against SARS-CoV-2 infection. Chen W; Liang B; Wu X; Li L; Wang C; Xing D J Pharm Anal; 2023 Mar; 13(3):255-261. PubMed ID: 36345404 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]